Most cancer drugs that kill tumors also damage healthy tissue. That is not a flaw in the design — it is the fundamental problem that oncology has been trying to solve for decades. And it is the problem that Stipple Bio, a Cambridge-based biotechnology company that emerged from stealth this…

The optimism lasted exactly one month. In February, the Massachusetts Business Confidence Index had crossed the line separating pessimism from optimism for the first time in a year—a small but significant respite for the state’s employers after months of mounting uncertainty. In March, that relief vanished. The AIM Business Confidence…

Cambridge-based Biogen announced it will acquire Apellis Pharmaceuticals, headquartered in Waltham, in an all-cash deal worth approximately $5.6 billion — or $41 per share. When Apellis stock closed on Monday, it was trading at roughly half that. By Tuesday morning, shares had more than doubled overnight. That kind of move…